Maria D. S.
- Country
- Germany
- Department
- Urologische Klinik
Research Overview
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 308 of 537 partner sites.
Specializations
Prostate Cancer Research
Specialized focus on metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), investigating novel therapeutic approaches.
- Hormone Therapy Combinations
- Novel Drug Development
- Targeted Therapies
Particular interest in treatment strategies involving enzalutamide combinations and new therapeutic agents for advanced disease states.
Bladder Cancer Innovations
Expert in treating various stages of bladder cancer, from non-muscle invasive bladder cancer to muscle-invasive urothelial carcinoma.
- Intravesical Therapies
- Immunotherapy Applications
- Perioperative Treatment
Focuses on innovative combination approaches including immunotherapy and targeted treatments for bladder cancer management.
Renal Cell Carcinoma Studies
Dedicated to advancing treatment options for advanced renal cell carcinoma and clear cell renal cancer.
- Adjuvant Therapy Development
- Targeted Treatment Combinations
- Post-Nephrectomy Care
Specializes in evaluating novel therapeutic combinations and immunotherapy approaches for kidney cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.